These studies revealed that all disease models were sensitive to treatment with noncompetitive LSD1 inhibitors and that seclidemstat treatment disrupted FET fusion activity in all the cell lines tested, as seen for SP-2509 in Ewing sarcoma. Here, KDM1A is linked to Ewing sarcoma.